Enthusiasm about the approach to cancer treatment could trigger some creative deal-making
This image shows pancreatic cancer cells (nuclei in blue) growing as a sphere encased in membranes. National Cancer Institute/USC Norris Comprehensive Cancer Center
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox.
Never before have I covered so much positive news about pancreatic cancer in such a short period of time. What happens next? Could Revolution Medicines buy Tango Therapeutics? Or, perhaps Bristol Myers Squibb goes all out and acquires Revolution Medicines?
To be clear, neither of these deals has been announced, or even rumored. I’m just playing the biotech M&A speculation game. But a strong case for something to happen can be made in the wake of Monday’s exciting report from Tango. In an early-stage clinical trial, patients with advanced pancreatic cancer benefited more from a combination of two targeted drugs — a PRMT5 inhibitor from Tango and Revolution’s pan-RAS inhibitor — than they might from each drug on its own.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus in-depth analysis, newsletters, premium events, and news alerts.
Already have an account? Log in
View All Plans
To read the rest of this story subscribe to STAT+.
Subscribe
Senior Writer, Biotech
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.
Read the full article at STAT News →📄Source document: National Cancer Institute/USC Norris Comprehensive Cancer Center
2 reports
STAT NewsIndependentCenter10 days agoThe article discusses potential mergers and acquisitions in the biotech industry driven by recent advancements in cancer treatment, specifically focusing on 'synthetic lethality' approaches. It highlights early-stage clinical trial results showing improved outcomes for patients with advanced pancreatic cancer using a combination of two targeted drugs.
Bias read (Center): The article focuses on scientific developments and potential business strategies within the biotech sector without taking a stance on political issues. It presents information objectively, discussing possible corporate actions based on medical research findings.
Official sources cited
- organisation National Cancer Institute/USC Norris Comprehensive Cancer Center
STAT NewsIndependentCenter13 days ago STAT+: Novo underwhelmed by drug it once fought Pfizer forThe article discusses various developments in the biotechnology sector, including challenges in paying for gene therapies, Novo's reduced enthusiasm for an obesity drug, Incyte's investment in blood disease research, and competition among obesity treatments. It also mentions Roche's partnership with Nurix Therapeutics for a potential blood cancer treatment and Revolution Medicines' promising results with a pancreatic cancer drug.
Bias read (Center): The article provides factual updates on pharmaceutical companies and their research without overtly favoring any political stance or ideology. The content focuses on business developments within the biotech industry and does not engage in ideological commentary or biased framing.
Official sources cited
- organisation Roche partners with Nurix Therapeutics for BTK-targeting antibody treatment
- organisation Revolution Medicines' pancreatic cancer drug shows high response rates
United States